| Literature DB >> 36006216 |
Youdan Zhang1,2, Xiaochen Zhang1,2, Jieming Zhang1,2, Shaukat Ali1,2, Jianhui Wu1,2.
Abstract
Studies on microorganism response spaceflight date back to 1960. However, nothing conclusive is known concerning the effects of spaceflight on virulence and environmental tolerance of entomopathogenic fungi; thus, this area of research remains open to further exploration. In this study, the entomopathogenic fungus Beauveria bassiana (strain SB010) was exposed to spaceflight (ChangZheng 5 space shuttle during 5 May 2020 to 8 May 2020) as a part of the Key Research and Development Program of Guangdong Province, China, in collaboration with the China Space Program. The study revealed significant differences between the secondary metabolite profiles of the wild isolate (SB010) and the spaceflight-exposed isolate (BHT021, BH030, BHT098) of B. bassiana. Some of the secondary metabolites/toxins, including enniatin A2, brevianamide F, macrosporin, aphidicolin, and diacetoxyscirpenol, were only produced by the spaceflight-exposed isolate (BHT021, BHT030). The study revealed increased insecticidal activities for of crude protein extracts of B. bassiana spaceflight mutants (BHT021 and BH030, respectively) against Megalurothrips usitatus 5 days post application when compared crude protein extracts of the wild isolate (SB010). The data obtained support the idea of using space mutation as a tool for development/screening of fungal strains producing higher quantities of secondary metabolites, ultimately leading to increased toxicity/virulence against the target insect host.Entities:
Keywords: entomopathogenic fungi; pathogenicity; secondary metabolites; space exposure
Mesh:
Year: 2022 PMID: 36006216 PMCID: PMC9416017 DOI: 10.3390/toxins14080555
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 5.075
Figure 1Total protein content of the crude protein extracts of the wild isolate (SB010) and spaceflight mutants (SCPH0535) of Beauveria bassiana. Error bars indicate standard error of means. Bars having different letters are significantly different from each other (Tukey’s test at 5% level of significance).
Figure 2LC-MS analysis of the crude protein extracts from the wild isolate and spaceflight mutants of Beauveria bassiana. The indicated peaks (circle) show the variation in secondary metabolite profile of spaceflight mutants from the wild isolates.
Figure 3Fourier transformation infrared (FTIR) spectroscopy of the crude protein extracts of wild isolate (SB010) and spaceflight mutants (BHT021, BHT030, and BHT098) of Beauveria bassiana. The indicated peaks (circle) show the variation in secondary metabolite profile of spaceflight mutants from the wild isolates.
Figure 4Nuclear magnetic resonance (NMR) resonance analysis of the crude protein extracts of wild isolate (SB010) and spaceflight mutants (BHT021, BHT030, and BHT098) of Beauveria bassiana. The indicated peaks (circle) show the variation in secondary metabolite profile of spaceflight mutants from the wild isolates.
Dose–mortality responses of M. usitatus adults to crude protein extracts of wild isolate (SB010) and spaceflight mutants (BHT021, BHT030, and BHT098) of Beauveria bassiana.
| Treatments | Concentration | Mortality (%) |
|---|---|---|
|
| ddH2O | 5.00 j |
| 100 | 88.33 ab | |
| 75 | 80.00 c | |
| 50 | 73.33 d | |
| 25 | 65.00 ef | |
| 12.5 | 50.00 h | |
|
| ddH2O | 5.00 j |
| 100 | 100.00 a | |
| 75 | 91.67 ab | |
| 50 | 83.33 bc | |
| 25 | 70.00 e | |
| 12.5 | 63.33 f | |
|
| ddH2O | 5.00 |
| 100 | 95.00 a | |
| 75 | 83.33 | |
| 50 | 75.00 d | |
| 25 | 63.33 f | |
| 12.5 | 56.67 g | |
|
| ddH2O | 5.00 j |
| 100 | 81.67 c | |
| 75 | 73.33 d | |
| 50 | 61.67 f | |
| 25 | 55.00 g | |
| 12.5 | 46.67 i |
The difference between the means (±SE) followed by various letters is significant (Tukey’s p < 0.05).
Figure 5Transmission electron microscopic examination of M. usitatus following treatment with mycelial extracts from Beauveria bassiana wild isolate and space mutants. Arrow marks points with variations in M. usitatus midgut anatomy following different treatment.